Two ways people chase growth hormone, one's an oral drug, one's an injectable peptide, and neither is offered here. What actually separates them.
Raises GH and IGF-1 and stimulates appetite; studied for body composition and sleep.
Grade C, human GH/IGF-1 data exists; long-term outcome and safety data limited.
Effects on long-term glucose metabolism and cardiac parameters need more data.
Studied as a selective GH secretagogue for recovery and sleep interest.
Grade C, selective GH secretagogue; human outcome data limited.
Human outcome data is limited; long-term effects are uncharacterized.
These get compared constantly, but they're different kinds of thing. MK-677 (ibutamoren) is an orally-active, non-peptide ghrelin-receptor agonist that keeps GH and IGF-1 elevated around the clock, convenient, but with appetite, blood-sugar and water-retention trade-offs. Ipamorelin is an injectable, selective peptide secretagogue that adds a cleaner pulse. Both are education-only here: MK-677 isn't a peptide and isn't FDA-approved; Ipamorelin acetate is withdrawn on the 503A side and still annotated Category 2 under FDA's 503B interim policy — non-compoundable either way.
Neither is offered by Peptós.LIFE. MK-677's sustained GH/IGF-1 elevation carries real metabolic cautions (glucose, fluid retention); both are WADA-banned (S2). The legal GH-axis route is Sermorelin.
They're different: MK-677 is an oral non-peptide that keeps GH/IGF-1 elevated continuously (with appetite and glucose trade-offs); ipamorelin is an injectable peptide that adds a cleaner, more pulsatile release. Neither is offered here, MK-677 isn't FDA-approved and ipamorelin is non-compoundable.
No. MK-677 (ibutamoren) is an orally-active non-peptide ghrelin-receptor agonist. It's often discussed alongside peptides but isn't one.